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Purpose
We investigated the effects of laminin on the fraction of cells with self-renewing capacity in
the estrogen-dependent, tamoxifen-sensitive LM05-E breast cancer cell line. We also 
determined whether laminin affected the response to tamoxifen. 
Materials and Methods
The LM05-E breast cancer cell line was used as a model for all experiments. Aldehyde dehy-
drogenase (ALDH) activity, clonogenic and mammosphere assays were performed to meas-
ure the effects of laminin on modulation of the stem cell subpopulation. Pluripotent gene
expression was analyzed by reverse transcriptase–polymerase chain reaction. The involve-
ment of the mitogen-activated protein kinase (MAPK)/ERK pathway was determined using
specific inhibitors. The effects of laminin on the response to tamoxifen were determined and
the involvement of 6 integrin was investigated. 
Results
We found that pretreatment with laminin leads to a decrease in cells with the ability to form
mammospheres that was accompanied by a decrease in ALDH activity. Moreover, exposure
of mammospheres to laminin reduced the capacity to form secondary mammospheres and
decreased the expression of Sox-2, Nanog, and Oct-4. We previously reported that 4-OH-
tamoxifen leads to an increase in the expression of these genes in LM05-E cells. Treatment
with signaling pathway inhibitors revealed that the MAPK/ERK pathway mediates the effects
of laminin. Finally, laminin induced tamoxifen resistance in LM05-E cells through 6 integrin. 
Conclusion
Our results suggest that the final number of cells with self-renewing capacity in estrogen-
dependent breast tumors may result from the combined effects of endocrine treatment
and microenvironmental cues. 
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Introduction
Seventy-five percent of women diagnosed with breast can-
cer have estrogen receptor (ER) and progesterone receptor–
positive breast tumors [1,2]. Tamoxifen, which is a selective
ER modulator, is the main 5-year adjuvant treatment for
these patients [3]. However, one third of tamoxifen treated
patients have recurrence within the first 15 years [4]. 
Tumors are complex organs composed of fibroblasts,
blood vessels, immune cells, extracellular matrix, and neo-
plastic cells [5]. Evidence suggests that both tumor progres-
sion and response to therapy are modulated by the tumor
microenvironment [6,7]. Indeed, several papers have impli-
cated stromal signatures as predictors of response to therapy
in breast cancer [8,9]. Moreover, resistance to tamoxifen is 
associated with the overexpression of an extracellular matrix
gene cluster [10,11]. We previously showed that fibronectin
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confers tamoxifen resistance through interaction with 1 
integrin [7].   
There is consistent evidence suggesting that stem cells
drive the growth and spread of breast tumors [12]. Moreover,
several studies have shown that these cells are more resistant
to conventional and endocrine therapy [13,14]. However,
there is little evidence confirming the effects of the tumor 
microenvironment on regulation of the stem cell compart-
ment. A few studies have shown involvement of extracellular
matrix on the differentiation of embryonic stem cells in 
endoderm induction [15,16]. However, to the best of our
knowledge, only one investigation of breast cancer has
shown that the extracellular matrix leads to an increase in
cells with stem cell properties [17]. 
We recently characterized the spontaneous M05 mouse
mammary tumor that arose in a BALB/c mouse in our ani-
mal facility, and showed that it is estrogen dependent and
tamoxifen sensitive in early passages, then progresses to 
endocrine resistance [18]. From this tumor, we generated a
bicellular cell line, LM05-Mix, composed of both epithelial
and fibroblastic cells that were subsequently separated to
generate the epithelial LM05-E and fibroblastic LM05-F cell
lines, respectively [19]. In LM05-E cells, we demonstrated
that exposure to tamoxifen leads to an increase in cells with
mammosphere forming capacity, which is in agreement with
other studies [20,21].
The present study was conducted to further analyze regu-
lation of the stem cell compartment in estrogen responsive
breast cancer cell lines. In particular, we explored the effects
of the extracellular matrix component laminin on LM05-E
cells. We also studied the effects of this protein on the pro-
portion of cells with stem cell properties. Our results suggest
that for ER-positive breast cancer cells, exposure to the 
extracellular matrix component laminin leads to a decrease
in cells with stem cell properties though the mitogen-acti-
vated protein kinase (MAPK)/ERK pathway, contrary to
what is observed in response to tamoxifen. We also found
that laminin produces resistance to tamoxifen induced cell
death through 6 integrin. These findings suggest that, for
ER-positive breast tumors, laminin modulates the final pro-
portion of stem cells and the response to endocrine treat-
ments such as tamoxifen.
Materials and Methods
1. Cell culture
The LM05-E cell lines were routinely maintained in growth
medium consisting of Dulbecco's modified Eagle's medium
(DMEM)/F12 (Sigma-Aldrich, St. Louis, MO) supplemented
with 10% fetal calf serum (FCS; GenSA, Buenos Aires, 
Argentina) and gentamicin in a humidified 5% CO2/air 
atmosphere. Serial passages were conducted by treatment of
80% confluent monolayers with 0.25% trypsin (Invitrogen,
Carlsbad, CA) and 0.02% EDTA in Ca2+-free and Mg2+-free
phosphate buffered saline (PBS).
2. Cell treatments
To evaluate the effects of laminin, 500,000 cells were plated
in 60 mm culture plates in growth medium. The next day,
cells were washed twice with PBS and then treated in phenol
red free DMEM/F12 with 1% charcoal stripped FCS (chsFCS)
and 17--estradiol (Sigma-Aldrich) at a final concentration of
10 nM. To test the role of laminin (Upstate Biotechnology,
Lake Placid, NY), it was added at a final concentration of 2
µg/mL, after which samples were incubated for 48 hours.
Mouse laminin purified from the Engelbreth Holm Swarm
mouse tumor was used for all experiments. The laminin con-
centration was based on previous reports by other authors
working with breast cancer cells [22] and our own prelimi-
nary observations. The following specific inhibitors were
used during analyses: MAPK pathway inhibitor PD98059 
(10 µM, Calbiochem, Darmstadt, Germany), phosphoinosi-
tide 3-kinase (PI3K)/AKT pathway inhibitor LY294002 
(10 µM, Calbiochem). At least 1,000 stock solutions of the
inhibitors were prepared in dimethyl sulfoxide (DMSO), and
the equivalent dilutions of DMSO were used as controls. A
30-minute pretreatment with the inhibitors was conducted
in each case before the 48-hour treatment. 
We previously showed that treatment of LM05-E cells with
4-OH-tamoxifen leads to cell death based on a terminal 
deoxynucleotidyl transferase dUTP nick end labeling assay
(In Situ Cell Death Detection Kit, Flourescein, Roche Applied
Science, Bromma, Sweden) or propidium iodide (PI) exclu-
sion [7,19] in growth medium; therefore, the same protocol
was used in this paper. Briefly, 35,000 cells were plated in
eight well LabTek chamber slides (Nunc, Thermo Fisher Sci-
entific, Roskilde, Denmark) in growth medium. The next
day, samples were washed twice with phenol red free
DMEM/F12, after which they were treated in the same cul-
ture medium supplemented with 1% chsFCS. 17--Estradiol
(Sigma-Aldrich) was used at a final concentration of 10 nM,
while 4-OH-tamoxifen (Sigma-Aldrich) was applied at 1 µM,
as previously described [7]. Laminin (2 µg/mL) or bovine
serum albumin (as a control) were also added at the time of
treatment. To determine the involvement of 6 integrin, cells
were pre-incubated for 15 minutes with the GoH3 mono-
clonal antibody (0.15 µg/mL, Santa Cruz Biotechnology
[Santa Cruz, CA], purchased as azide and endotoxin free
reagent) or with control pre-immune IgG (Santa Cruz
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Biotechnology, purchased as azide and endotoxin free
reagent) before being plated in the chamber slides. The same
procedure was used for the AIIB2 1 integrin blocking anti-
body (0.15 µg/mL, Aragen Bioscience, Morgan Hill, CA) as
previously described [7]. Antibodies were added to the cul-
ture medium when the treatments were started. After 48
hours of treatment, slides were washed with PBS, and cells
were incubated for 1 minute in a PI solution (50 µg/mL in
PBS, Sigma-Aldrich), washed in PBS, and fixed with 4% for-
malin in PBS for 10 minutes. Nuclei were counterstained
with 4,6-diamino-2-phenylindole (DAPI, Research Organics
Inc., Cleveland, OH), after which slides were mounted with
Vectashield (Vector Laboratories, Burlingame, CA). Experi-
ments were conducted in triplicate, and 10 random fields
with an average of 200 cells/field were counted per well. The
percentage of PI-positive cells relative to the total number of
cells (stained with DAPI) was calculated as a measure of cell
death and expressed as % dead cells, as previously described
[7]. Images were taken using a Nikon TE2000S (Tokyo,
Japan) inverted fluorescent microscope and counted using
the Image Pro Plus software (MediaCybernetics Inc., Silver
Spring, MD). 
3. Mammosphere assays 
Single cell suspensions derived from the LM05-E cell line
were plated in 6-well low attachment suspension culture
plates (Greiner Bio-One, Koln, Germany) or 2% agarose
coated plates (for LM05-E cells) at a density of 10,000 viable
cells/mL. Cells were grown in 2 mL serum-free media sup-
plemented with B27 (Gemini Bioproducts, West Sacramento,
CA) and 20 ng/mL epidermal growth factor as previously
described [14]. Mammospheres were counted after 5-8 days
in culture using a Nikon Eclipse TE2000-S inverted micro-
scope. To dissociate mammospheres to obtain single cell sus-
pensions, spheres were centrifuged and resuspended in 100
µL of 0.25% trypsin and 0.53 mM EDTA, then incubated for
5-10 minutes at 37ºC. Serum was added to stop the reaction,
after which it was subjected to gentle pipetting and centrifu-
gation. Finally, cells were resuspended in medium.
4. Aldehyde dehydrogenase activity
The Aldefluor kit (Stem Cell Technologies, Vancouver,
Canada) was used to determine the percentage of aldehyde
dehydrogenase (ALDH)–positive cells in the LM05-E cell line
according to the manufacturer's instructions. Green fluores-
cence, which is produced as a result of ALDH activity, was
analyzed by fluorescence-activated cell sorting analysis
(PASIII, PARTEC, Munich, Germany).  
5. Clonogenic assays
Single cell suspensions derived from the LM05-E cell line
were plated in 24-well culture plates at a density of 200
cells/well. Cells were grown in 0.5 mL of growth medium
for 7 days, after which the wells were washed and cells were
fixed with methanol: acetic acid (3:1 v/v) and then stained
with crystal violet. Colonies of at least eight cells were
counted using a binocular microscope.
6. Reverse transcriptase–polymerase chain reaction
RNA from subconfluent monolayers or from mammos-
phere cultures was prepared using TRIzol Reagent (Invitro-
gen Life Technologies). cDNA was prepared using an iScript
cDNA synthesis kit (BioRad, Richmond, CA). PCR products
were obtained using the mouse primers Nanog, Sox2, and
Oct4 previously published by Zhang et al. [23].
7. Western blot 
Subconfluent monolayers or mammosphere derived cells
were pretreated with laminin for different lengths of time,
after which cells were washed twice with ice-cold PBS,
scraped with a Teflon scraper and finally lysed with 1% Tri-
ton X-100 in PBS. After protein determination, samples were
denatured by boiling in sample buffer with 5% -mercap-
toethanol and then run in 10% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis, with 50 µg of protein loaded
into each lane. Gels were subsequently blotted to Hybond-P
membranes and incubated for 1 hour in blocking buffer con-
taining 5% skim milk and 0.1% Tween-20 in PBS with p-ERK
antibody (E-4: sc-7383, Santa Cruz BD, Dallas, TX), ERK1/2
antibody (MK1: sc-135900, Santa Cruz BD), or 6 integrin 
antibody (N-19: sc-6597, Santa Cruz BD) overnight at 4°C,
followed by 1 hour of incubation with a secondary antibody
coupled to horseradish peroxidase. Samples were then sub-
jected to chemiluminescence analysis, after which bands
were digitalized with a Photo/Analyst Express System 
(Fotodyne Inc., Hartland, WI) and signal intensity was quan-
tified with the Gel-Pro Analyzer software (Media Cybernet-
ics, Rockville, MD).
8. Statistical analysis
Significant differences among assays were identified by the
Student’s t test or one or two way ANOVA, followed by Bon-
ferroni’s comparisons test. A value of p < 0.05 was consid-
ered significant.
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Results
1. Laminin reduces the proportion of cells with stem cell
properties
The LM05-E breast cancer cell line is ER-positive and sen-
sitive to tamoxifen [19]. We have previously shown that this
cell line can form mammospheres and that this capacity is
increased by tamoxifen [14]. In this study, the effects of
laminin on the proportion of cells with stem cell properties
were analyzed. To accomplish this, adherent cells were cul-
tured in DMEM/F12 with 1% chsFCS and estradiol 10 nM
supplemented with 2 µg/mL laminin or vehicle for 48 hours,
after which the mammosphere-forming efficiency was 
assessed. After 48 hours, treatment was interrupted and cells
were seeded into nonadherent plates under mammosphere
forming conditions. As shown in Fig. 1A, laminin reduced
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Fig. 1. Laminin leads to a reduction in cells with mammosphere forming capacity and a decreased proportion of aldehyde
dehydrogenase (ALDH)–positive cells. (A) LM05-E cells were treated for 48 hours in Dulbecco's modified Eagle's medium
(DMEM)/F12 medium with 1% charcoal stripped fetal calf serum (chsFCS) and 10 nM estradiol supplemented with vehicle
(control) or 2 µg/mL laminin (LN). Cells were then trypsinized, washed and plated on non-adherent 6-well plates at a density
of 10,000 cells/mL in mammosphere medium as explained in the “Materials and Methods.” The graphs show the number
of mammospheres/10,000 cells after 6 days. A representative mammosphere is shown on the right. A significant reduction
in mammosphere forming capacity was observed. (B) LM05-E cells were initially treated as in panel A, then maintained in
growth medium (GM) for 1 month before conducting the mammosphere assays, as shown in the diagram above the graph.
Even after 1 month in culture, a significant decrease in mammosphere forming capacity was observed for both cell lines. 
(C) Representative analysis of flow cytometries of cells treated (left) or untreated cells (right) with the ALDH inhibitor DEAB.
Region 2 (R2) indicates cells that are considered positive in this assay. (Continued to the next page)
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the mammosphere forming efficiency of LM05-E cells. More-
over, after treatment, cells were washed and then maintained
under normal culture conditions for 1 month, at which time
the mammosphere forming efficiency was assessed. The 
results observed after the additional month of culture were
the same as those observed after the first 48-hour treatment,
indicating that the effects of the initial treatment were sus-
tained (Fig. 1B). No morphological changes were observed
in the cells. 
ALDH1 is a marker of stem cells [24]. To investigate the 
effects of laminin on the proportion of ALDH-positive cells,
LM05-E cells were treated with laminin as explained above
(for 48 hours on plastic), after which cells were processed as
described in the materials and methods. Fig. 1C shows the
representative flow cytometries of control cells to define the
ALDH-positive cell regions. Fig. 1D shows the representative
flow cytometries of cells treated with laminin and Fig. 1E dis-
plays the quantification of three independent experiments.
The results indicate that laminin reduces the proportion of
ALDH-positive cells, reinforcing the previous findings. 
2. Laminin reduces the clonogenic efficiency of LM05-E
mammospheres
We showed that laminin reduced the proportion of cells
with stem cell properties. Next, the effects of laminin on the
clonogenic efficiency of LM05-E mammospheres were stud-
ied. To accomplish this, mammospheres were cultured for
10 days, then supplemented with laminin (2 µg/mL) or 
vehicle. Forty-eight hours later, mammospheres were disag-
gregated and seeded to study the clonogenic efficiency. As
shown in Fig. 2, there was a significant decrease in the clono-
genic efficiency of cells derived from mammospheres treated
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Fig. 1. (Continued from the previous page) (D) LM05-E cells were treated for 48 hours in DMEM/F12 with 1% chsFCS and 10
nM estradiol supplemented with vehicle (control) or 2 µg/mL LN. Cells were then trypsinized, washed and stained using
the Aldefluor Kit (Stem Cell Technologies), after which they were analyzed by flow cytometry. Tubes without DEAB are
shown and cells within region 2 are considered positive. (E) Quantification of the ALDH-positive cells is shown. One of at
least three experiments is shown in each case (**p < 0.01, ***p < 0.001).
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Fig. 2. Laminin (LN) reduces the clonogenic efficiency of
mammospheres. Ten-day-old LM05-E mammospheres of
LM05-E cells were treated for 48 hours with 2 µg/mL LN
or vehicle (control). Mammospheres were then dissociated
and single cells were seeded at a concentration of 200 cells
per well in 24-well plates in growth medium. Colonies of
at least eight cells were counted after 7 days of culture.
One of at least three experiments is shown (*p < 0.05). 
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with laminin relative to the controls, suggesting that 
microenvironmental factors lead to cell differentiation and a
reduction in the number of cells with stem cell properties. 
3. Laminin induces differentiation of cells with stem cell
properties
Considering that there is a reduction in the clonogenic 
potential of cells derived from mammospheres after treat-
ment with laminin, we investigated whether these proteins
induce cell differentiation. To accomplish this, mammos-
pheres were treated with laminin as described above. Fol-
lowing treatment, mammospheres were disaggregated and
seeded under mammosphere forming conditions and the
number of secondary mammospheres was determined. As
shown in Fig. 3A, for LM05-E, this matrix element reduced
the number of secondary mammospheres, indicating that
mammospheres contained less cells with self-renewing 
capacity after treatment. We next assessed if treatment with
laminin modulated the expression of genes involved in stem
cell self-renewal. We previously showed that a 5-day treat-
ment with 4-OH-tamoxifen led to enrichment in cells with
stem cell properties in the LM05-E cell line, as well as an 
increase in self renewal-associated gene expression [14]. In
this context, we tested whether laminin could regulate the
expression of genes associated with self-renewal after expo-
sure to 4-OH-tamoxifen. To accomplish this, LM05-E cells
were plated in cell culture dishes and treated with 4-OH-
tamoxifen for 5 days as previously described [14]. Cells were
then washed and cultured in growth medium for one week.
The adherent cells were subsequently treated as described
above for 48 hours with laminin or vehicle, after which the
RNA was extracted. The gene expression study revealed that
laminin reduced Nanog, Sox2, and Oct-4 expression after 
tamoxifen treatment (Fig. 3B).    
4. The MAPK/ERK pathway mediates the effects of
laminin over the stem cell population
As shown above, laminin induced differentiation and 
reduced the proportion of cells with stem cell properties. We
next proceeded to determine if either the PI3K/AKT or
MAPK/ERK pathways were involved in this effect. To do so,
LM05-E cells were subjected to a 30 minute pre-treatment
with LY294002 (PI3K/AKT inhibitor) or PD98059 (MEK 
inhibitor). Next, laminin or vehicle was added to the cultures
for 48 hours, after which mammosphere assays were con-
ducted. As shown in Fig. 4A, treatment with the PI3K/AKT
pathway inhibitor alone had an effect on LM05-E cells, indi-
cating that cells with stem cell properties are dependent on
this pathway. Fig. 4B shows that PD98059 inhibited the 
reduction in the number of mammospheres induced by the
Cancer Res Treat. 2017;49(4):869-879
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Fig. 3. Laminin (LN) induces differentiation of cells with stem cells properties. (A) Ten-day-old LM05-E mammospheres
were supplemented for 48 hours with vehicle (control) or 2 µg/mL LN, then dissociated and seeded at a concentration of
10,000 cells per well in 6-well low attachment culture plates under mammosphere forming conditions. The number of mam-
mospheres was quantified after 6 days. (B) LM05-E cells were pretreated with Dulbecco’s modified Eagle’s medium/F12,
1% charcoal stripped fetal calf serum supplemented with 10 nM estradiol and 1 µM 4-OH-tamoxifen or vehicle (control) for
5 days. Subsequently, cells were washed and cultured in growth medium for 1 week, after which they were treated with 
vehicle (control) or 2 µg/mL LN for 48 hours. Finally, RNA was extracted to investigate the gene expression of Nanog, Sox
2, Oct-4, and glyceraldehyde 3-phosphate dehydrogenase (GADPH) using reverse transcriptase–polymerase chain reaction.
Treatment with LN led to a decrease in the expression levels of genes associated with self-renewal. One of at least three 
experiments is shown for each case (**p < 0.01).
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microenvironmental factor laminin in the LM05-E cell line.
Western blot analysis of cells treated with laminin showed
that this extracellular matrix component activates the MAPK/
ERK pathway in this cell line, as expected (Fig. 4C). These 
results indicate that the MAPK/ERK signaling pathway 
mediates the effects of laminin over the stem cell population
in this ER-positive breast cancer cell line.
5. Laminin induces tamoxifen resistance in LM05-E cells
through 6 integrin 
We previously showed that fibronectin confers tamoxifen
resistance to LM05-E cells through 1 integrin [7]. Based on
the effects of laminin on the stem cells population of the
LM05-E line observed herein, we investigated whether
laminin conferred tamoxifen resistance as well. To explore
this possibility, cells were treated with 4-OH-tamoxifen for
48 hours in the presence of laminin (2 µg/mL). We found no
increase in cell death under these conditions (Fig. 5A). To 
determine if the protective effects of laminin were mediated
by 6 integrin, a well-established laminin receptor, western
blot analysis of the protein extracts was conducted to confirm
the expression of this specific integrin (Fig. 5B). Next, LM05-
E cells were pre-incubated with the GoH3 6 integrin block-
ing antibody, then seeded on laminin. Treatment with GoH3
dramatically reduced the protective effects of laminin on 
tamoxifen-induced cell death (Fig. 5C). Interestingly, AIIB2,
a 1 integrin blocking antibody previously shown to revert
fibronectin’s protective effect [7], did not affect laminin-
induced endocrine resistance (Fig. 5D). Thus, our results
show that, like fibronectin, laminin is able to induce tamox-
ifen resistance in LM05-E cells, and that in this case, 6 inte-
grin mediates the protective effect. 
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Discussion
In this study, we demonstrated that the microenvironmen-
tal factor laminin reduces the proportion of cells capable of
forming mammospheres or with high ALDH1 activity
through the MAPK/ERK pathway, while also inducing 
tamoxifen resistance through 6 integrin. It has been previ-
ously determined that cells capable of forming mammos-
pheres have stem cell properties [25], and that ALDH1 is a
marker of normal and malignant breast cancer stem cells [24].
Based on these findings, we conclude that laminin reduces
the proportion of cells with stem cell properties in the murine
LM05-E cell line. Furthermore, we showed that these effects
were abolished if an inhibitor of the MAPK/ERK pathways
was used, indicating the involvement of this pathway in the
Cancer Res Treat. 2017;49(4):869-879
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Fig. 5. Laminin (LN) induces tamoxifen resistance in LM05-E cells through integrin 6. (A) LM05-E cells were treated with
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previously described effect. We also demonstrated that treat-
ment with laminin reduces the clonogenic potential of cells
obtained from mammospheres and their capacity to form
secondary mammospheres. Taken together, these results 
indicate that the number of cells with stem cells properties
is diminished after treatment. Based on these findings, we
assessed whether laminin was inducing differentiation by
studying the expression of genes related to self-renewal. We
previously showed that treatment of LM05-E cells with 
4-OH-tamoxifen leads to an increase in the expression of
genes associated with self-renewal and mammosphere form-
ing capacity [14]. Therefore, we tested whether this effect
could be counteracted by laminin. We found that this was
the case, suggesting that the final number of stem cells in 
tamoxifen responsive breast cancer may result from the com-
bined effects of treatment and the context. 
To the best of our knowledge, only one other study has 
investigated the effects of extracellular matrix elements and
cells with stem cell properties in breast cancer. Specifically,
Saha et al. [17] studied the effects of laminin on neoplastic
mouse mammary H605 cells. They found that microenviron-
mental elements led to an increase in the proportion of cells
with stem cell properties using similar experimental 
approaches. The fact that these results are opposed to ours
may be due to differences in experimental models. Specifi-
cally, H605 cells were obtained from primary cultures of a
tumor derived from a 6-month-old Her2/neu-transgenic
mouse [17]. However, similar results to ours have been 
reported in the context of extracellular matrix and stem cells
during development. For example, Taylor-Weiner et al. [15]
showed that laminin-111 is necessary for endoderm differ-
entiation of embryonic stem cells. Moreover, other authors
showed that 1 integrin, which is the main receptor for 
extracellular matrix components, is also necessary for defin-
itive endoderm differentiation [16]. Additionally, Prowse et
al. [26] demonstrated that the MAPK/ERK and Rho-ROCK
pathways are involved in signaling of extracellular matrix 
elements in embryonic stem cells. Other authors have 
reported that integrins and extracellular matrix elements are
involved in the self-renewal, proliferation [27] and differen-
tiation [28] of embryonic stem cells. 
We previously showed that the extracellular matrix com-
ponent fibronectin induces tamoxifen resistance in LM05-E
cells [7]. In the present study, we demonstrated that laminin
is able to induce endocrine resistance. In addition, we showed
that tamoxifen treatment selects for cells with stem cell prop-
erties, leading to sustained enrichment of these cells in the
LM05-E cell line [14]. Here, we show that cell lines with a
high proportion of cells with stem cell properties after tamox-
ifen treatment respond to laminin by reducing this cell pop-
ulation, demonstrating the increased complexity of the
relationship between cells and the microenvironment. Inter-
estingly, we found that the effects of laminin are sustained
over time, as indicated by cells exposed to laminin for 48
hours and then cultured in its absence for one month retain-
ing a reduced number of mammosphere forming cells.
Laminin has previously been shown to induce epigenetic
changes in breast cancer cells [29,30]. Thus, in the context of
our results we hypothesize that a mechanism of this type
could be involved. Moreover, the effects of laminin on ER-
expression levels in the context of breast cancer stem cells
have not been analyzed in this paper. Others have previously
shown that laminin-1 increases the expression levels of ER-
in functionally normal primary mouse mammary epithelial
cells [31]. Laminin induces differentiation of cells with stem
cell properties, but also stimulates tamoxifen resistance.
However, it remains to be determined if the reduction in the
proportion of cells with stem cell properties induced by
laminin modulates tamoxifen resistance in the LM05-E cell
line or if it is an independent effect. 
Our results suggest that the final number of cells with self-
renewing capacity in estrogen dependent breast tumors may
result from the combined effect of endocrine treatment and
microenvironmental cues. Further studies may reveal how
strategies geared toward modulating the microenvironment
may potentiate endocrine treatment in breast cancer and
avoid enrichment in cells with stem cell properties. 
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